Erik L Munson
Overview
Explore the profile of Erik L Munson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo J, Warner T, Munson E, Nardelli D, Schell R
Pathog Dis
. 2016 Aug;
74(7).
PMID: 27493062
Interleukin-17 (IL-17) has been shown to participate in the development of Lyme arthritis in experimental mice. For example, neutralization of IL-17 with antibodies inhibits induction of arthritis in Borrelia-primed and...
2.
Nardelli D, Luedtke J, Munson E, Warner T, Callister S, Schell R
FEMS Immunol Med Microbiol
. 2010 Jul;
60(1):78-89.
PMID: 20662925
The immunological events leading to the development of Lyme arthritis in humans are partially understood. Much of this information has been gained by studying the course of infection of naïve...
3.
Nardelli D, Munson E, Callister S, Schell R
Future Microbiol
. 2009 May;
4(4):457-69.
PMID: 19416014
The development of a vaccine for Lyme disease was intensely pursued in the 1990s. However, citing a lack of demand, the first human Lyme disease vaccine was withdrawn from the...
4.
Munson E, Doern G
J Clin Microbiol
. 2007 Oct;
45(12):4051-3.
PMID: 17942653
The biotypes of Haemophilus influenzae and Haemophilus parainfluenzae isolates were determined with three commercially available biochemical test kits: the IDS RapID NH system, the Neisseria-Haemophilus identification test (NHI card), and...
5.
Munson E, Nardelli D, Luk K, Remington M, Callister S, Schell R
Clin Vaccine Immunol
. 2006 Jan;
13(1):19-25.
PMID: 16425995
Determination of the immunological mediators responsible for promoting the production of borreliacidal antibody may facilitate the development of an improved borreliosis vaccine for human and veterinary use. Previously, we developed...
6.
Munson E, Heard S, Doern G
Chest
. 2004 Nov;
126(5):1628-35.
PMID: 15539737
Objective: Use of central venous catheters (CVCs) impregnated with minocycline and rifampin reduces the density of bacterial growth on catheters and decreases the incidence of catheter-related bloodstream infections. Questions have...
7.
Munson E, DeCoster D, Nardelli D, England D, Callister S, Schell R
Clin Diagn Lab Immunol
. 2004 Jan;
11(1):35-41.
PMID: 14715542
Development of a high level of sustained borreliacidal antibody is paramount for maintaining protection against infection with Borrelia burgdorferi. We show that production of borreliacidal antibody can be enhanced by...
8.
Christopherson J, Munson E, England D, Croke C, Remington M, Molitor M, et al.
Clin Diagn Lab Immunol
. 2003 Jan;
10(1):44-52.
PMID: 12522038
We found that Borrelia burgdorferi-vaccinated gamma interferon-deficient (IFN-gamma(0)) mice challenged with B. burgdorferi developed prominent chronic destructive osteoarthropathy. When these mice were treated with anti-tumor necrosis factor alpha (TNF-alpha) antibody,...
9.
Munson E, Diekema D, Beekmann S, Chapin K, Doern G
J Clin Microbiol
. 2003 Jan;
41(1):495-7.
PMID: 12517905
We analyzed antimicrobial use in 509 episodes of clinically significant bloodstream infection to assess the impact that microbiology laboratory reporting had on antimicrobial management. Most therapy interventions occurred at the...
10.
Munson E, Pfaller M, Doern G
J Clin Microbiol
. 2002 Nov;
40(11):4285-8.
PMID: 12409411
Pseudomonas aeruginosa is an important cause of community-associated and nosocomial infections related to exposure to aqueous environments. Such infections often occur in the setting of a common-source outbreak, in which...